Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a combined treatment using KarXT and KarX-EC in adults aged 55 to 90 years who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study is sponsored by Bristol-Myers Squibb and aims to address agitation symptoms in this population by comparing the study drugs against placebo. Participants have a confirmed Alzheimers diagnosis and agitation symptoms as defined by recognized criteria. Participants receive either the combined drugs KarXT and KarX-EC or a placebo, with doses given on specified days. The study is designed with parallel groups and maintains blinding to ensure unbiased results. This treatment period lasts 14 weeks, during which the effects on agitation and related symptoms are closely monitored. During the trial, participants and their caregivers attend regular visits to assess changes in agitation using established tools like the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association CMAI-IPA and other scales. Safety is monitored through adverse event tracking, physical exams, laboratory tests, vital signs, and electrocardiograms. The study also evaluates cognitive and behavioral changes up to 18 weeks, with caregivers playing a key role in reporting participant status and medication adherence.
Actively Recruiting
Researchers are evaluating DT120, a psychoactive drug acting mainly on serotonin 2A receptors, for treating adults aged 18 to 74 with major depressive disorder MDD. This Phase 3 trial compares DT120 to placebo over 12 weeks in a double-blind, randomized, and triple-blind design to assess its efficacy and safety. Participants must have a confirmed diagnosis of MDD with specific symptom severity and duration, without major psychiatric or unstable medical conditions. The study includes a 12-week double-blind period where participants receive a single dose of either DT120 at one of two dose levels or placebo. This is followed by a 40-week open-label extension phase where all participants may receive DT120 with monitoring for retreatment based on safety and symptoms. The trial evaluates multiple outcomes related to depression severity, symptom improvement, anxiety, sexual function, quality of life, and work productivity. Participants will undergo regular assessments including depression rating scales like MADRS and CGI, anxiety scales, and questionnaires on sexual functioning and daily activity impact. Monitoring continues throughout the extension phase to assess treatment durability and response. The total participation may last up to 52 weeks, with evaluations at several timepoints to understand treatment effects and safety over both study phases.
Actively Recruiting
Researchers are investigating the long-term safety and effectiveness of a combined drug treatment using xanomeline tartratetrospium chloride in an immediate release capsule KarXT and xanomeline enteric capsules KarX-EC for people with agitation linked to Alzheimers Disease. This study is an open-label extension of earlier studies CN012-0023 and CN012-0024. It aims to understand how well these treatments work over time and monitor any side effects. Participants who completed the previous studies will receive specified doses of KarXT and KarX-EC according to a set schedule. This phase 3 study does not include a comparison group and all participants receive the combined treatment. The treatment period lasts approximately 30 weeks, during which the effects and safety of these medications will be observed. During the study, participants will be closely monitored for any adverse events, changes in cognitive function, movement disorders, vital signs, and other health measures. Assessments include scales like the Mini-Mental State Examination MMSE, Abnormal Involuntary Movement Scale AIMS, and others related to agitation and side effects. Safety checks such as lab tests, ECGs, and questionnaires will be regularly conducted. The total study duration for participants is about 30 weeks, with follow-up to evaluate overall treatment tolerability and impact.
Actively Recruiting
Researchers are exploring how nurses perceive and practice family engagement in Emergency Departments and how family members experience care in this setting. This observational study aims to describe these interactions and understand what helps or hinders family involvement during emergency care. The study is sponsored by Mayo Clinic and involves multiple international sites. The study involves interviews with two groups registered professional nurses responsible for patient care plans in the Emergency Department and family members who feel a sense of belonging to a patient admitted to the Emergency Department. Nurses will be asked about their approaches to working with families and factors affecting family engagement. Family members will share their experiences being with their loved ones in the Emergency Department. Participants will be interviewed, and the study will record the number of nurse and family member participants. The interviews aim to gather detailed descriptions of family engagement practices and experiences. Participants must be adults and able to communicate in English for the U.S. part of the study. The study will last until December 2027, with no treatment given, focusing on collecting qualitative data about family involvement in emergency care.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of two drugs, EXV-802 and EXV-801, for treating agitation in people with Alzheimers Disease dementia. This Phase 23 study uses a double-blind, placebo-controlled design and includes approximately 300 participants diagnosed with Alzheimers-related agitation using standardized criteria and biomarker confirmation. The study is conducted at multiple centers across the US, Canada, and Europe. Participants are randomly assigned to one of three groups receiving EXV-802 capsules, EXV-801 capsules, or placebo capsules, each taken twice daily for six weeks. Screening occurs about four weeks before randomization to ensure eligibility, and the study follows a parallel model comparing these three arms. Treatment adherence and response are carefully monitored during this period. During the study, participants undergo assessments including the Cohen-Mansfield Agitation Inventory CMAI-IPA to measure agitation changes from baseline to week 6, and the Clinical Global Impression of Severity CGI-S scale to evaluate symptom severity. Caregivers must be involved and regularly in contact with participants. Safety and efficacy data are collected throughout, with the study expected to complete by early 2029.